NuvOx Pharma Announces FDA Acceptance of IND to Initiate Clinical Trial for Vaso-Occlusive Crisis in Sickle Cell Disease

The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to infection, stroke, multisystem organ damage, and shortened life expectancy. A type of VOC is ACS, which is one of the leading causes of death in these patients. Hypoxia, a low oxygen state in tissues, contributes to the underlying processes in both VOC and ACS. NVX-508 is designed to deliver oxygen to the diseased tissues in patients with sickle cell disease. Evan Unger MD, President and CEO of NuvOx Pharma said, “Acceptance of the IND is a major accomplishment for us. We can now proceed with clinical studies in this indication.”

Click here for full article